Outcome
    Limited
    Effectiveness 2/5

    Nattokinase for Fibrinogen Reduction

    Nattokinase has genuine fibrinolytic activity in the lab, but human trials are small and mostly from a narrow group of investigators.

    Overview

    Nattokinase has genuine fibrinolytic activity in the lab, but human trials are small and mostly from a narrow group of investigators.

    Verdict

    Mixed evidence

    Plausible but under-evidenced. Never a substitute for prescribed anticoagulation.

    How It Works

    Nattokinase is a serine protease from fermented soy that degrades fibrin directly and enhances endogenous fibrinolysis by increasing tissue plasminogen activator activity.

    Dosing & Protocol

    Typical dose

    Recommended dose
    2000 FU daily
    Expected timeframe
    8-12 weeks

    Protocol

    form
    Nattokinase standardised in fibrinolytic units (FU), ideally vitamin K2-reduced if you take warfarin - though see the safety note
    duration
    8-12 weeks, with fibrinogen rechecked
    co factor
    Take on an empty stomach, since food slows absorption of this enzyme, and away from any anticoagulant medication. Evidence is mixed. Nattokinase is a serine protease from fermented soybeans with demonstrated fibrinolytic activity in vitro, capable of degrading fibrin directly and of enhancing endogenous fibrinolysis by affecting plasminogen activator inhibitor-1. Small human trials, mostly in Asian populations and often industry-linked, report reductions in plasma fibrinogen, factor VII and factor VIII, alongside modest blood pressure lowering. The trials are small, short and inconsistently designed, clinical endpoints such as thrombosis or cardiovascular events have never been studied, and how much of an orally administered protease survives digestion intact remains genuinely contested.
    titration
    Up to 4,000 FU/day; most trials used 2,000-4,000 FU/day
    starting dose
    2,000 FU (about 100 mg) once daily on an empty stomach

    Evidence

    What the studies say

    Small randomised trials report reduced plasma fibrinogen, factor VII and factor VIII, plus modest blood pressure reduction. Study sizes are typically under 100 participants, follow-up is short, and no trial has measured cardiovascular events.

    A single-dose of oral nattokinase potentiates thrombolysis and anti-coagulation profiles

    Score: 5/10
    2015
    crossover
    n=12

    A single-dose of 2,000 FU nattokinase potentiated thrombolysis and anti-coagulation profiles in healthy male subjects.

    View source

    Safety

    Caveats

    Increases bleeding risk, particularly with warfarin, DOACs, aspirin or before surgery. Stop two weeks before any procedure. Avoid with a history of haemorrhagic stroke.

    Less likely to help if

    People with normal fibrinogen and no inflammatory driver.

    Medical Disclaimer

    The information provided on this website is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any supplement regimen.

    Individual results may vary. The statements on this website have not been evaluated by the Food and Drug Administration. Products and information are not intended to diagnose, treat, cure, or prevent any disease.